1.33% -0.001

Hepion Pharmaceuticals Inc (HEPA)

개요 뉴스 가격 이력 Financials 토론 예측 주식 분할

Relative Volume:

Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile

Hepion Pharmaceuticals Inc

Healthcare (1081)

Biotechnology (607)

최신 SEC 제출 서류

HEPA's Discussions on Twitter

Compare HEPA vs VRTX, REGN, ARGX, MRNA, RVMD

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
HEPA Hepion Pharmaceuticals Inc	0.074	0	0	-2.98M	-1.71M	-0.259
VRTX Vertex Pharmaceuticals Inc	552.85	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	833.56	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,019.49	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	158.83	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.38	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2020-07-20	재개	ROTH Capital	Buy

Hepion Pharmaceuticals Inc 주식(HEPA)의 최신 뉴스

Hepion Pharmaceuticals Inc (HEPA) 재무 분석

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile

Compare HEPA vs VRTX, REGN, ARGX, MRNA, RVMD

Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades

Hepion Pharmaceuticals Inc 주식(HEPA)의 최신 뉴스

Hepion (HEPA) grants interim CEO 1.35M options at $0.08 - Stock Titan

Hepion chair granted 1.35M options at $0.08 | HEPA Insider Trading - Stock Titan

Hepion Pharmaceuticals (HEPA) gives VP 1.35M options at $0.08 - Stock Titan

Hepion (HEPA) director awarded 299K stock options - Stock Titan

Hepion Pharmaceuticals (HEPA) awards director 299K stock options - Stock Titan

Hepion Pharmaceuticals (HEPA) awards 299K options to director - Stock Titan

Hepion Pharmaceuticals Appoints James Liddy to Board of Directors - Minichart

Hepion appoints James Liddy to its board - TradingView

Hepion (NASDAQ: HEPA) COO locks in 2M warrants at $0.06 - Stock Titan

Hepion (HEPA) chairman-led group builds 26M-share stake - Stock Titan

Black Global 5 Llc Net Worth (2026) - GuruFocus

Wednesday’s insider buys and sells: Hepion insiders invest $800K By Investing.com - Investing.com Nigeria

Hepion Pharmaceuticals, Inc. Q2 2026: Revenue $0 Net loss $(1.25M), EPS $(0.08) — 10-Q Summary - TradingView

Hepion Pharmaceuticals director Stetz buys $25,000 in common stock By Investing.com - Investing.com Nigeria

Hepion Pharmaceuticals director Michael Purcell buys $100,000 in stock By Investing.com - Investing.com Australia

Hepion Pharmaceuticals director Stetz buys $25,000 in common stock - Investing.com

Hepion Pharmaceuticals interim CEO Gary Stetz buys $100,000 in stock - Investing.com

Hepion Pharmaceuticals interim CEO Gary Stetz buys $100,000 in stock By Investing.com - Investing.com South Africa

Hepion COO Sireesh Appajosyula buys $100,000 in common stock By Investing.com - Investing.com Nigeria

Hepion COO Sireesh Appajosyula buys $100,000 in common stock - Investing.com

Hepion Pharmaceuticals executive chairman LoPriore buys $500,000 in stock - Investing.com

Hepion Pharmaceuticals executive chairman LoPriore buys $500,000 in stock By Investing.com - Investing.com India

Hepion Pharmaceuticals (HEPA) director purchases 500K shares and 500K warrants - Stock Titan

Hepion Pharmaceuticals (NASDAQ: HEPA) director purchases 2M shares and 2M warrants - Stock Titan

Hepion Pharmaceuticals (HEPA) interim CEO Stetz buys 4M shares and warrants - Stock Titan

Hepion Pharmaceuticals (HEPA) chair LoPriore reports 20M-share and warrant purchases - Stock Titan

Hepion Pharmaceuticals director Michael Purcell buys $100,000 in stock - Investing.com

Hepion Pharmaceuticals (HEPA) holder reports 10M warrants and 10M shares - Stock Titan

Darin Feinstein Discloses Investment at Hepion Pharmaceuticals with 11.1% Stake - TradingView

Investor buys 10M Hepion Pharmaceuticals (HEPA) shares plus warrant - Stock Titan

Hepion Pharmaceuticals (HEPA) completes $3.06M exempt securities sale under Rule 506(b) - stocktitan.net

Hepion Pharmaceuticals Announces New Private Placement Financing - TipRanks

Hepion Pharmaceuticals, Inc. announced that it has received $3.055 million in funding - marketscreener.com

Hepion Pharmaceuticals, Inc. Revenue Breakdown – OTC:HEPA - TradingView

Hepion Pharmaceuticals, Inc. Revenue Breakdown – OTC:CTRVP - TradingView

Hepion Pharmaceuticals (HEPA) Proxy Filing Summary - Quartr

Hepion Pharmaceuticals (HEPA) Proxy filing Summary - Quartr

Hepion Pharmaceuticals (HEPA) Q4 2025 earnings summary - Quartr

Hepion Pharmaceuticals (HEPA) director Stetz submits initial insider Form 3 - Stock Titan

Hepion Pharmaceuticals (HEPA) director Danina Fisher files initial Form 3 - Stock Titan

Hepion Pharmaceuticals keeps the focus on its pipeline - AD HOC NEWS

Two new directors join Hepion Pharmaceuticals (OTC: HEPA) board - Stock Titan

Hepion Pharmaceuticals updates CRV431 liver program, shares follow biotech peers - Ad-hoc-news.de

Enterprise value to revenue forward of Hepion Pharmaceuticals, Inc. – OTC:HEPA - TradingView

Hepion Pharmaceuticals, Inc. Actuals & Estimates (OTC:HEPA) - TradingView

Enterprise value to EBIT forward of Hepion Pharmaceuticals, Inc. – OTC:CTRVP - TradingView

Price to book forward of Hepion Pharmaceuticals, Inc. – OTC:CTRVP - TradingView

Price to sales forward of Hepion Pharmaceuticals, Inc. – OTC:CTRVP - TradingView

Price to earnings forward of Hepion Pharmaceuticals, Inc. – OTC:CTRVP - TradingView

Hepion Pharmaceuticals Inc (HEPA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Hepion Pharmaceuticals Inc (HEPA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Hepion Pharmaceuticals Inc (HEPA) 재무 분석

매출

순이익

현금흐름

주당 순 이익

HEPA과 유사한 종목